115 related articles for article (PubMed ID: 6138855)
1. Travellers' diarrhoea: prospects for successful immunoprophylaxis.
Levine MM
Scand J Gastroenterol Suppl; 1983; 84():121-34. PubMed ID: 6138855
[TBL] [Abstract][Full Text] [Related]
2. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
Leyten EM; Soonawala D; Schultsz C; Herzog C; Ligthelm RJ; Wijnands S; Visser LG
Vaccine; 2005 Oct; 23(43):5120-6. PubMed ID: 15982790
[TBL] [Abstract][Full Text] [Related]
3. Adhesion of enterotoxigenic Escherichia coli in humans and animals.
Levine MM
Ciba Found Symp; 1981; 80():142-60. PubMed ID: 6114818
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.
Behrens RH; Cramer JP; Jelinek T; Shaw H; von Sonnenburg F; Wilbraham D; Weinke T; Bell DJ; Asturias E; Pauwells HL; Maxwell R; Paredes-Paredes M; Glenn GM; Dewasthaly S; Stablein DM; Jiang ZD; DuPont HL
Lancet Infect Dis; 2014 Mar; 14(3):197-204. PubMed ID: 24291168
[TBL] [Abstract][Full Text] [Related]
5. Bacterial enteric infections and vaccine development.
Holmgren J; Svennerholm AM
Gastroenterol Clin North Am; 1992 Jun; 21(2):283-302. PubMed ID: 1512046
[TBL] [Abstract][Full Text] [Related]
6. Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli.
Lasaro MO; Luiz WB; Sbrogio-Almeida ME; Ferreira LC
Vaccine; 2005 Mar; 23(19):2430-8. PubMed ID: 15752829
[TBL] [Abstract][Full Text] [Related]
7. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.
Frech SA; Dupont HL; Bourgeois AL; McKenzie R; Belkind-Gerson J; Figueroa JF; Okhuysen PC; Guerrero NH; Martinez-Sandoval FG; Meléndez-Romero JH; Jiang ZD; Asturias EJ; Halpern J; Torres OR; Hoffman AS; Villar CP; Kassem RN; Flyer DC; Andersen BH; Kazempour K; Breisch SA; Glenn GM
Lancet; 2008 Jun; 371(9629):2019-25. PubMed ID: 18554712
[TBL] [Abstract][Full Text] [Related]
8. Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea.
Svennerholm AM; Holmgren J; Sack DA
Vaccine; 1989 Jun; 7(3):196-8. PubMed ID: 2675484
[TBL] [Abstract][Full Text] [Related]
9. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.
Levine MM; Kaper JB; Black RE; Clements ML
Microbiol Rev; 1983 Dec; 47(4):510-50. PubMed ID: 6363898
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for enterotoxigenic Escherichia coli: current status.
Boedeker EC
Curr Opin Gastroenterol; 2005 Jan; 21(1):15-9. PubMed ID: 15687879
[TBL] [Abstract][Full Text] [Related]
11. Epitope analysis of the CS3 fimbrial subunit of human enterotoxigenic Escherichia coli and the construction of novel CS3::ST and CS3::LT-B immunogens.
Yakhchali B; Manning PA
Behring Inst Mitt; 1997 Feb; (98):124-34. PubMed ID: 9382733
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS.
López-Gigosos R; García-Fortea P; Reina-Doña E; Plaza-Martín E
Travel Med Infect Dis; 2007 Nov; 5(6):380-4. PubMed ID: 17983977
[TBL] [Abstract][Full Text] [Related]
13. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study.
Steinsland H; Valentiner-Branth P; Gjessing HK; Aaby P; Mølbak K; Sommerfelt H
Lancet; 2003 Jul; 362(9380):286-91. PubMed ID: 12892959
[TBL] [Abstract][Full Text] [Related]
14. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
15. [Continuous and common epitopes present in fimbriae of enterotoxigenic Escherichia coli (ETEC)].
López-Vidal Y
Gac Med Mex; 1997; 133(6):511-25. PubMed ID: 9504082
[TBL] [Abstract][Full Text] [Related]
16. Experimental enterotoxin-induced Escherichia coli diarrhea and protection induced by previous infection with bacteria of the same adhesin or enterotoxin type.
Ahrén CM; Svennerholm AM
Infect Immun; 1985 Oct; 50(1):255-61. PubMed ID: 2864313
[TBL] [Abstract][Full Text] [Related]
17. Vaccines against enterotoxigenic Escherichia coli.
Svennerholm AM; Tobias J
Expert Rev Vaccines; 2008 Aug; 7(6):795-804. PubMed ID: 18665777
[TBL] [Abstract][Full Text] [Related]
18. Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli.
Qadri F; Ahmed T; Ahmed F; Bhuiyan MS; Mostofa MG; Cassels FJ; Helander A; Svennerholm AM
Infect Immun; 2007 May; 75(5):2269-74. PubMed ID: 17296752
[TBL] [Abstract][Full Text] [Related]
19. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
Walker RI
Vaccine; 2005 May; 23(26):3369-85. PubMed ID: 15837361
[TBL] [Abstract][Full Text] [Related]
20. Review article: prevention and treatment of travellers' diarrhoea.
Farthing MJ
Aliment Pharmacol Ther; 1991 Feb; 5(1):15-30. PubMed ID: 1932478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
